Cello Buys Biopharma Insights Firm Advantage Healthcare

Healthcare and consumer marketing business Cello Group has acquired US-based biopharma analysis and insights business Advantage Healthcare. Cello will pay an initial $1.5m in cash and a deferred consideration of up to $3m, dependent on financial performance to June 2021.

Founded by Debbie Glick (pictured) more than twenty years ago, Princeton, New Jersey-based Advantage Healthcare provides insights and analysis to support new products and business development. Her team works with sources including global data sets, various primary methodologies, competitive and business intelligence, and analytics, to provide support for product forecasts and market sizing exercises. For the year to 31st December 2016, the firm had an unaudited turnover of $4.5m, gross profit of $3.0m, and unadjusted operating profit of $0.3m. Additionally, as at 31st December 2016, the business had unaudited net assets of $0.4m.

Cello Health says the acquisition will complement its existing capabilities in consulting, market research and science-based communications; while also extending its ability to work from the early stages of drug development and across the life cycle. US CEO Julia Ralston says of the buy: 'We are delighted to welcome Advantage Healthcare to the Cello Health family as they further support our focus in providing high value, strategic advisory services to our biopharmaceutical clients globally. We look forward to adding this team's wealth of experience, gained from both Advantage's work portfolio over the years and senior positions held within the industry'.

Web sites: www.cellohealth.com and www.advantageh.com .